LY264826 (A82846B) is a naturally-occurring glycopeptide antibiotic, differing from vancomycin in the stereochemistry of the amino-sugar of the disaccharide function, and the presence of a third sugar attached at the benzylic position of amino acid residue 6. Despite these seemingly subtle differences, LY264826 is approximately 10 times more active than vancomycin against the enterococci. In the pursuit of new antibiotics active against multiresistant Gram-positive organisms, an extensive side chain SAR was developed focusing on the reductive alkylation of LY264826 at the amino function of the disaccharide moiety. A new series of derivatives having varying degrees of structural diversity in the side chain (e. g. varying lengths and degrees of rigidity) was found to have potent activity
The urgent medical need created by the recent emergence of drug resistant bacteria has intensified the search for more effective clinical agents. In particular, vancomycin-resistant enterococci (VRE) and methicillinresistant Staphylococcus aureus (MRSA) are no longer treatable with traditional antibiotics. Currently, vancomycin ( Fig. 1 ) is the drug of choice for serious enterococcal infections and is the only antibiotic that is effective in treating resistant strains of S, aureus1,2).
Recent advances with respect to the chemical derivatization of the vancomycin-related glycopeptide class of natural products have given researchers new opportunities to discover more effective clinical agents3,4). While most chemical modifications to vancomycin offer some advantages, alkylation of a related glycopeptide, LY264826 significantly improves activity against VRE.
As reported in an earlier publication, the promising activity of the chlorobenzyl derivative of LY264826 prompted a structure-activity relationship (SAR) focused on substituted benzyl derivatives of LY2648265). Herein we report our findings for the extensive side chain SAR centered on the N-alkylation of the disaccharide amino group (N1) of LY264826 (Scheme 1). This research build on the discovery of the initial lead compound LY191145 and resulted in the discovery of the present clinical We selected the p-chlorobenzyl derivative (LY191145), the first compound to demonstrate activity which might to further investigate the effects of the side chain on antimicrobial activity. Further variation of the benzyl class of side chains with other halogen functional groups resulted in a series of novel derivatives. As shown (Table  1) , the para bromo and iodo analogs, like the chloro However, the derivative with the fluoro benzyl side chain only maintained the activity found with the natural halogen type, we observed that the aryl substitution pattern was also tied to activity. For example, the chloro substituent residing in the para position retained better overall activity. As the side chain SAR was extended to include other classes of side chains, the aryl substitution pattern was seen again as an important structural feature.
As we explored the total benefits of attaching different functional groups to the benzylic side chain, we revisited the early side chain SAR performed on vancomycin which focused on the effects of linear aliphatic side chains (e. g. n-decyl), similar to those found naturally in teicoplanin ( Table 2 ). The aliphatic side chain SAR on vancomycin demonstrated that these side chains had a positive effect on antimicrobial activity3,10) Likewise, the coupling of long aliphatic side chains to LY264826, resulted in an approximate 16-fold improvement in VRE activity over the natural products, including teicoplanin.
Although, the effects of this modification towards activity against sensitive enterococci was minimal, the combination of a lipophilic side chain with an aryl ring proved to be a winning combination to improve overall antimicrobial activity. The alkyloxy benzyl class is one example where activity against resistant and sensitive enterococcus was clearly demonstrated (Table 3) . The shortest side chain in this series, the methoxy benzyl (C l)
shows an overall improvement in activity compared to the non substituted benzylic side chain. As the side chain length was extended from Cl to Cl2, we observed a minimum and maximum of biological activity. The pentyloxobenzyl derivative (CS) imparted the best overall activity against the pathogens tested, in particular resistant and sensitive enterococci and S. heamolyticus. A similar result occurred with the alkylbenzyl series.
However, in this case, the SAR was optimized with a four carbon chain length. A similar trend is observed for a series of phenyl alkyl side chains, where the aromatic ring is removed from the point of attachment, repositioned, and linked at the tail end of the aliphatic tether.
As shown graphically (Fig. 2) , as the tether length was increased from C1 to C12, the mean MIC's against VRE (Table 4) . These polyaromatic derivatives revealed that a second aromatic ring produced one of most active compounds in this SAR. These biphenyls showed a substantial improvement in overall activity staphylococci. This result prompted us to take a look at the effects of a third aromatic ring. We were encouraged to observe that this side chain showed promising activity against resistant and sensitive enterococci. However, the additional aromatic ring effected a slight decrease in contrast to the mono benzyl series, there was no major advantage to impact biological activity by increasing the chain length with aliphatic "tails". Examination of other polyaromatic derivatives, where multiple aromatic rings are linked in the ortho, meta, para, or fused at the ortho-meta or meta-para positions, showed improvements in activity against the resistant enterococci. As illustrated in (Table 5) , the effect on VRE activity was correlated to the degree of steric bulk nearest the site of attachment. As a second or third aromatic ring was incorporated in the side chain that resulted in a non-para arrangement of the aromatic rings (e. g. 1-naphthalene and anthracene), the overall enterococci activity decreased. If suitable modifications were made such that the steric bulk is positioned away from the site of attachment; a para or meta-para orientation (e. g. biphenyl benzyl, 2-naphthalene), the activity against resistant and sensitive enterococci was restored and enhanced. Unfortunately, the activity against S. aureus did not improve with the more bulky polyaromatics. The effect of bulky side chains on antimicrobial activity was seen with a series of multicyclic analogs. The multicyclic derivatives (Table 6 ) afforded minimal improvement in activity against both VRE and MRSA as compared with the linear aliphatic/aryl alkyl side chains described earlier.
The incorporation of a second aromatic ring in the side chain was an important breakthrough in the SAR.
We elaborated on side chains containing two aromatic rings to further pinpont the geometric requirements that would impact activity. A series of biphenyl derivatives coupled with -CH2-, -CHOH-, -S-, -N-, -O-linkers were investigated (Table 7) . Examination of these derivatives illustrates that excellent activity against VRE did not require a linear geometry. With the exception of linker types with hydrogen bonding potential (e. g. -NH-, -CHOH-), these linkers were well tolerated. Of As the phenyl benzyl side chain SAR was evaluated, we found that the degree and type of unsaturation was important to maintain activity. As shown (Table 8) , complete saturation of one or two of the aromatic rings show increased activity toward both enterococci and staphylcocci over the natural products, LY264826, but the structural features provided by two aromatic rings was overall more active than the saturated analogs. Likewise replacement of one aromatic ring with heterocycles such as the thiophene group (bioisotere) provided no significant advantage over the phenyl benzyl analog, but as with most of the modifications described, we observed excellent activity against VRE and MRSA as compared to LY264826.
We continued to explore the features that enhance activity among the mono benzyl derivatives with the phenyl benzyl series. Differences in trends were found among the different classes of side chains. For example, unlike the alkyloxy mono benzyl series, the attachment of alkyloxy side chains did not yield a compound better than the parent compound, phenyl benzyl ( Table 9 ). The minimum chain length (-OCH3) retained activity similar to that of the parent compound. As the length of the flexible lipophilic "tail" was increased to C5, the activity against VRE remained unchanged but the activity against staphylococci was impaired. Furthermore, the staphylococcal activity was dramatically diminished by alkyl chain lengths of six or more carbons. The functional groups found to be the most effective substituents with the mono benzyl side chains produced the most active compounds in the phenyl benzyl series ( 
